Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Phys Clinical Casesoncological

Phys Clinical Cases · oncological

Immune Checkpoint Inhibitor Toxicity — DCE Clinical Case

DCE long-case and short-case clinical station for immune checkpoint inhibitor toxicity: comprehensive patient assessment, presentation and discussion for a 64-year-old man on combination ipilimumab-nivolumab for metastatic melanoma who develops multisystem immune-related adverse events (grade 3 colitis, hypophysitis with secondary adrenal insufficiency, grade 2 hepatitis, and a grade 2 maculopapular rash), including the CTCAE grading framework, the steroid-dose ladder, second-line infliximab and mycophenolate, the permanent-discontinuation decision, and a focused general-examination routine with the troponin-for-chest-pain rule.

8 min readVerification in progress

Target exams

FRACP DCEMRCP PACES
On this page
Study tools

Target exams

FRACP DCEMRCP PACES
Prompt
DCE long-case and short-case clinical station for immune checkpoint inhibitor toxicity: comprehensive patient assessment, presentation and discussion for a 64-year-old man on combination ipilimumab-nivolumab for metastatic melanoma who develops multisystem immune-related adverse events (grade 3 colitis, hypophysitis with secondary adrenal insufficiency, grade 2 hepatitis, and a grade 2 maculopapular rash), including the CTCAE grading framework, the steroid-dose ladder, second-line infliximab and mycophenolate, the permanent-discontinuation decision, and a focused general-examination routine with the troponin-for-chest-pain rule.

The patient

Mr K is a 64-year-old retired engineer who was diagnosed with metastatic melanoma (BRAF wild-type, PD-L1 positive) eight months ago. He commenced combination ipilimumab and nivolumab four months ago and has tolerated the first three cycles well, with a partial response on the most recent CT. Three weeks ago he developed loose stools, which have progressed to eight bloody bowel motions per day with mucus, abdominal cramps and urgency. Over the same period he has noticed a diffuse itchy rash over his trunk, profound fatigue, and dizziness on standing. He has lost 4 kg. He is otherwise well, takes no regular medications, and has no prior autoimmune disease. [1]

Examination findings

  • General: alert but fatigued, mildly jaundiced. Diffuse maculopapular rash over the trunk, confluent, involving approximately 25 per cent of body surface area. No mucosal involvement.
  • Vital signs: heart rate 108, blood pressure 104/62 lying and 88/54 standing, respiratory rate 20, oxygen saturation 96 per cent on room air, temperature 37.4.
  • Abdomen: diffuse tenderness, no peritonism, bowel sounds hyperactive, no organomegaly.
  • Respiratory: fine bibasal crackles.
  • Cardiovascular: no murmur, no rub, no raised JVP.
  • Neurological: no ptosis, no fatigability, no focal deficit, GCS 15.
  • Endocrine: no thyroid bruit, no hyperpigmentation; confrontation visual fields show a mild bitemporal restriction. [1]

Investigations

  • Sodium 126, potassium 5.1, urea 9.2, creatinine 140 (baseline 88).
  • ALT 260, AST 210, ALP 180, bilirubin 58, INR 1.3, albumin 28.
  • Haemoglobin 112, white cells 14.6, eosinophils 0.4, platelets 230.
  • TSH 16.4 mU/L (high), free T4 6 pmol/L (low), random cortisol 70 nmol/L (low), ACTH 5 ng/L (low), FSH low, LH low, testosterone low, prolactin mildly raised.
  • Troponin normal. ECG normal sinus rhythm.
  • Stool culture, C. difficile toxin, ova cysts and parasites sent, results pending.
  • Hepatitis A, B, C and E serology, CMV and EBV PCR, autoimmune markers — pending.
  • Abdominal ultrasound with Doppler — pending. [1]
Physician Medicine Pro

Continue reading

You have read the opening of this clinical case. The complete unit — every section and its primary-source references — is part of the Physician Medicine fellowship library.

Sign in to continueSee pricing
References9ShowHide
  1. [1]Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med, 2010.PMID 20525992
  2. [2]Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med, 2012.PMID 22658127
  3. [3]Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol, 2017.PMID 28881921
  4. [4]Brahmer JR, Lacchetti C, Thompson JA, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol, 2018.PMID 29442540
  5. [5]Postow MA, Sidlow R, Hellmann MD Immune-Related Adverse Events Associated with Immune Checkpoint Blockade N Engl J Med, 2018.PMID 29320654
  6. [6]Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol, 2018.PMID 29567210
  7. [7]Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis JAMA Oncol, 2018.PMID 30242316
  8. [8]Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials J Clin Oncol, 2017.PMID 28841387
  9. [9]Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis J Crohns Colitis, 2017.PMID 28204866
Physician Medicine Pro

$29/ monthor $279 / year

The complete Physician Medicine library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousCancer Cachexia AND Nutritional Support — DCE Clinical CaseoncologicalNextOncologic Emergencies — DCE Clinical Caseoncological